Peter Borchmann

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster, Michael Bishop, Constantine S. Tam et al. · New England Journal of Medicine · 2018 · 4K citations · Full text

Medicine, Hematology, Oncology +15

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

Andreas Engert, Annette Plütschow, Hans Theodor Eich et al. · New England Journal of Medicine · 2010 · 921 citations · Full text

Medicine, Oncology, Chemotherapy +8

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

Bertrand Coiffier, Barbara Pro, H. Miles Prince et al. · Journal of Clinical Oncology · 2012 · 674 citations

Medicine, Pharmacology, Pharmacotherapy +13

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

Andreas Engert, Heinz Haverkamp, Carsten Kobe et al. · The Lancet · 2012 · 632 citations

Medicine, Oncology, Radiation Oncology +15

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Hematology, Oncology +9